Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
29 Agosto 2024 - 9:00AM
Business Wire
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical
company focused on developing life-changing therapies for allergic
and immunologic diseases, today announced that it will participate
in the Morgan Stanley 22nd Annual Global Healthcare Conference on
September 5th in New York, New York.
About Astria Therapeutics: Astria Therapeutics is a
biopharmaceutical company, and our mission is to bring
life-changing therapies to patients and families affected by
allergic and immunologic diseases. Our lead program, navenibart
(STAR-0215), is a monoclonal antibody inhibitor of plasma
kallikrein in clinical development for the treatment of hereditary
angioedema. Our second program, STAR-0310, is a monoclonal antibody
OX40 antagonist in preclinical development for the treatment of
atopic dermatitis. Learn more about our company on our website,
www.astriatx.com, or follow us on X and Instagram @AstriaTx and on
Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240829008062/en/
Astria Contact: Investor
Relations and Media: Elizabeth Higgins
investors@astriatx.com
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Astria Therapeutics (NASDAQ:ATXS)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
